Hologic, Inc. $HOLX Shares Bought by BNP Paribas Financial Markets

Key Points

• BNP Paribas Financial Markets increased its stake in Hologic, Inc. by 28.4%, holding over 585,000 shares valued at approximately $36 million.
• Hologic reported earnings of $1.08 per share for the recent quarter, which exceeded analysts' expectations and reflects a 1.2% revenue increase year-over-year.
• Several analysts have upgraded Hologic's stock ratings, with Royal Bank of Canada raising its price target from $72 to $87, suggesting positive market sentiment.

BNP Paribas Financial Markets increased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 28.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 585,846 shares of the medical equipment provider's stock after buying an additional 129,534 shares during the quarter. BNP Paribas Financial Markets owned about 0.26% of Hologic worth $36,188,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new position in Hologic in the 1st quarter worth approximately $34,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in Hologic in the 1st quarter worth approximately $42,000. Raiffeisen Bank International AG bought a new position in Hologic in the 4th quarter worth approximately $49,000. Allworth Financial LP grew its holdings in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after buying an additional 722 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on HOLX shares. Morgan Stanley increased their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Finally, Citigroup raised Hologic from a "neutral" rating to a "buy" rating and increased their price target for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $78.00.

Hologic Price Performance

Shares of NASDAQ:HOLX traded up $0.37 on Friday, reaching $66.76. 1,270,243 shares of the company traded hands, compared to its average volume of 1,601,091. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The company's 50 day moving average is $66.34 and its 200-day moving average is $62.60. The stock has a market capitalization of $14.85 billion, a PE ratio of 27.70, a P/E/G ratio of 2.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the prior year, the firm earned $1.06 EPS. The company's quarterly revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.